Welcome to our dedicated page for ABEONA THERAPEUTICS SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ABEONA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ABEONA THERAPEUTICS's regulatory disclosures and financial reporting.
Abeona Therapeutics director Donald A. Wuchterl reported a small stock sale mainly for tax purposes. On 02/02/2026, he sold 14,814 shares of Abeona Therapeutics common stock at a weighted average price of $5.0906 per share to cover tax obligations from vesting restricted stock awards.
After this transaction, he directly owned 167,935 shares of Abeona common stock. The shares were sold in multiple trades within a narrow price range from $5.09 to $5.12 per share.
Abeona Therapeutics director Eric Crombez reported a sale of company stock. On 02/02/2026, he sold 16,284 shares of Abeona Therapeutics common stock at a weighted average price of $5.0906 per share in market transactions.
According to the disclosure, this sale was made to cover tax obligations arising from the vesting of restricted stock awards. After these transactions, Crombez beneficially owned 63,456 shares of Abeona Therapeutics common stock directly.
Abeona Therapeutics insider plans Rule 144 stock sale. A holder has filed to sell 14,814 shares of Abeona Therapeutics common stock, with an aggregate market value of $75,412.00, through Stifel Nicolaus on the Nasdaq exchange around 02/02/2026.
The shares relate to equity compensation: 36,101 common shares were acquired on 01/31/2026 via restricted stock units granted by the issuer and paid in equity. Common shares outstanding were 54,191,361 at the time of the notice.
A holder of ABEO common stock has filed a notice of proposed sale under Rule 144 to sell 16,284 shares through broker Stifel Nicolaus & Company Inc. on or about February 2, 2026 on the Nasdaq, with an aggregate market value of $82,886.00.
The filing notes that 36,101 common shares were acquired on January 31, 2026 as restricted stock units from the issuer as equity compensation. The issuer had 54,191,361 shares of this class outstanding at the time referenced.
Abeona Therapeutics insider Mark Alvino filed a notice of proposed sale of 2,000 shares of common stock. The shares are planned to be sold through Stifel Nicolaus & Company on Nasdaq around 02/02/2026, with an aggregate market value of $10,180.00.
The 2,000 shares were acquired on 01/31/2026 as restricted stock units granted by the issuer as equity compensation. Over the past three months, Alvino has already sold 15,000 and 13,500 common shares, generating gross proceeds of $71,168.00 and $70,574.00, respectively.
Abeona Therapeutics shareholder filed a notice of proposed sale under Rule 144 for 18,065 shares of common stock through Stifel Nicolaus & Company on 02/02/2026 on Nasdaq. The filing lists an aggregate market value of $91,962.00 for these shares and notes that 54,191,361 shares of common stock were outstanding.
The seller acquired 36,101 shares of common stock on 01/31/2026 via restricted stock units granted as equity compensation from the issuer, with payment also dated 01/31/2026. The form states the signer represents they are not aware of undisclosed material adverse information about Abeona’s current or prospective operations.
Abeona Therapeutics director Leila Alland reported selling 18,065 shares of common stock on February 2, 2026 at a weighted average price of $5.0906 per share. The sale was made to cover tax obligations from the vesting of restricted stock awards, and she now beneficially owns 173,614 shares directly.
Abeona Therapeutics director Mark Alvino reported a small share sale to cover taxes. On February 2, 2026, he sold 2,000 shares of common stock in Abeona Therapeutics at a weighted average price of $5.0906 per share.
The filing explains that the sale was made to satisfy tax obligations arising from the vesting of restricted stock awards, rather than as a discretionary portfolio decision. After this transaction, Alvino directly beneficially owned 84,065 shares of Abeona Therapeutics common stock, and no derivative securities were reported.
Abeona Therapeutics director Donald A. Wuchterl reported receiving 37,313 shares of common stock as restricted stock on January 26, 2026, at a price of $0.00 per share. After this grant, he directly holds 182,749 shares of Abeona common stock.
According to the filing, all of this restricted stock will vest on January 26, 2027, meaning the shares become fully owned by him on that date if the vesting conditions are met.
Abeona Therapeutics Inc. director Bernhardt G. Zeiher received a grant of 37,313 shares of common stock on January 26, 2026. The shares were awarded at a price of $0.00 per share as restricted stock. After this grant, he directly holds 84,458 shares. All of the restricted stock will vest on January 26, 2027, meaning the award becomes fully owned on that date if conditions are met.